As the TMPRSS2-ERG fusion is the most common genomic alteration in prostate cancer, and cell migration is a key component of metastasis, the high-affinity ERK2/ERG interaction represents a potential target for small molecule inhibition during prostate cancer treatment. The gene discussed is MAPK1; the disease is prostate carcinoma.